Medicare covers tirzepatide for type 2 diabetes through Part D prescription drug plans, where it is sold under the brand name Mounjaro. Medicare does not cover tirzepatide for weight loss, where it is sold as Zepbound. This distinction comes down to a longstanding federal law that prohibits Medicare from paying for drugs used for weight management, even when obesity contributes to serious health problems.
The practical reality is more complicated than a simple yes or no. Even when you qualify for coverage through a diabetes diagnosis, your actual cost and approval process depend heavily on which Part D plan you have, what rules that plan enforces, and whether you meet specific clinical criteria.
Why the Diagnosis Matters
Tirzepatide is FDA-approved for two separate uses under two brand names. Mounjaro treats type 2 diabetes. Zepbound treats obesity. Medicare Part D plans can cover Mounjaro for diabetes because it falls under standard prescription drug benefits. Zepbound, however, hits a wall: a 2003 federal statute explicitly excludes drugs used for “anorexia, weight loss, or weight gain” from Medicare coverage.
This means that if your doctor prescribes tirzepatide specifically to manage your blood sugar, your Part D plan can cover it. If the prescription is for weight loss alone, Medicare will deny it regardless of your plan. For people who have both type 2 diabetes and obesity, the prescription is typically written for diabetes management, which keeps it within the coverage rules.
What You’ll Actually Pay
Getting coverage approved doesn’t mean the drug is cheap. Tirzepatide’s list price runs over $1,000 per month, and your share depends on your plan’s formulary tier, deductible, and coinsurance structure. Under some Part D plans, the average monthly out-of-pocket cost for Mounjaro nearly doubled from 2024 to 2025, jumping from about $99 to $196 per month. The variation between plans is significant, so two Medicare beneficiaries on the same drug can pay very different amounts.
A White House deal with the manufacturer has promised to cap GLP-1 out-of-pocket costs at $50 per month for Medicare beneficiaries, which would substantially reduce what most people pay. The timing and implementation of that cap may vary, so checking with your specific plan about current pricing is worthwhile.
Prior Authorization and Step Therapy
Most Part D plans don’t simply fill a tirzepatide prescription without questions. You’ll likely face prior authorization, meaning your prescriber needs to demonstrate that the drug is medically necessary for your condition before the plan agrees to pay. In practice, this means submitting documentation of your type 2 diabetes diagnosis and often your history with other medications.
Many plans also require step therapy. This means you have to try one or more less expensive diabetes drugs first and show they didn’t adequately control your blood sugar before the plan will approve tirzepatide. Metformin and sulfonylureas are common first steps. Plans may also limit the quantity they’ll cover in a given time period.
If your plan denies coverage or imposes a restriction you believe is inappropriate, you have the right to request an exception. Your doctor must provide a supporting statement explaining why tirzepatide is medically necessary for you specifically, why alternative drugs would be less effective, or why switching to a different medication could cause negative health effects. Plans are required to review these requests and respond within set timeframes.
Lower Costs Through Extra Help
If you have limited income and resources, Medicare’s Extra Help program (also called the Low Income Subsidy) can dramatically reduce what you pay. For 2026, Extra Help eliminates your plan premium and deductible entirely. Your copayment drops to no more than $5.10 for generic drugs and $12.65 for brand-name drugs like Mounjaro. Once your total drug costs for the year reach $2,100 (including payments made on your behalf through the program), your copayment drops to $0 for the rest of the year.
People who qualify for both Medicare and full Medicaid coverage through the Qualified Medicare Beneficiary program pay even less: no more than $4.90 per covered drug. For someone facing a $196 monthly cost without assistance, these programs represent a massive difference.
The Push to Cover Weight Loss
The exclusion of weight loss drugs from Medicare has faced growing criticism as GLP-1 medications have shown benefits beyond the scale, including reduced heart attack and stroke risk. The Treat and Reduce Obesity Act of 2025, introduced in the House in June 2025, would remove the statutory ban on Medicare coverage of obesity medications. The bill has been referred to the House Committees on Energy and Commerce and Ways and Means, but it remains in the early “introduced” stage with no guarantee of passage.
Similar bills have been introduced in previous congressional sessions without becoming law. The cost implications are enormous: covering GLP-1 drugs for the millions of Medicare beneficiaries with obesity would add tens of billions to program spending, which makes the legislative path uncertain. For now, the diabetes indication remains the only route to Medicare coverage for tirzepatide.
How to Check Your Specific Plan
Because Part D is administered by private insurance companies under contract with Medicare, coverage details vary from plan to plan. The most reliable way to find out what you’ll pay is to log into your Medicare account at Medicare.gov and use the plan finder tool, which lets you search for Mounjaro on your specific plan’s formulary. You’ll see the tier it’s placed on, any restrictions like prior authorization or step therapy, and an estimate of your cost at different pharmacies.
If you’re choosing a new Part D plan during open enrollment, comparing how different plans handle tirzepatide can save you hundreds of dollars per year. Plans that place it on a preferred brand tier will cost you less than those listing it as a non-preferred specialty drug. The difference in tier placement alone can swing your monthly cost by $100 or more.